Wall Street analysts expect Becton, Dickinson and Company (NYSE:BDX) to report earnings of $2.43 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Becton, Dickinson and’s earnings, with the highest EPS estimate coming in at $2.51 and the lowest estimate coming in at $2.34. Becton, Dickinson and reported earnings of $2.33 per share in the same quarter last year, which indicates a positive year over year growth rate of 4.3%. The business is expected to report its next quarterly earnings results on Thursday, February 1st.

On average, analysts expect that Becton, Dickinson and will report full year earnings of $10.47 per share for the current fiscal year, with EPS estimates ranging from $10.41 to $10.65. For the next fiscal year, analysts forecast that the company will report earnings of $11.46 per share, with EPS estimates ranging from $11.23 to $11.63. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The firm’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.12 earnings per share.

Several equities analysts have weighed in on the company. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Zacks Investment Research lowered Becton, Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Wells Fargo & Company assumed coverage on Becton, Dickinson and in a research note on Friday, September 22nd. They issued an “outperform” rating and a $225.00 target price on the stock. Bank of America Corporation reissued a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Finally, BidaskClub raised Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and an average price target of $211.94.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The disclosure for this sale can be found here. In the last three months, insiders sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of BDX. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and in the first quarter valued at approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Becton, Dickinson and by 8.1% in the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 51 shares in the last quarter. Harfst & Associates Inc. grew its stake in Becton, Dickinson and by 46.4% in the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares in the last quarter. Finally, Financial Architects Inc grew its stake in Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after purchasing an additional 54 shares in the last quarter. Hedge funds and other institutional investors own 86.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate Becton, Dickinson and Company (BDX) Will Post Earnings of $2.43 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/04/zacks-analysts-anticipate-becton-dickinson-and-company-bdx-will-post-earnings-of-2-43-per-share.html.

Becton, Dickinson and (NYSE:BDX) opened at $224.41 on Friday. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The firm has a market cap of $50.98 billion, a PE ratio of 23.61, a PEG ratio of 1.77 and a beta of 1.04.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.